Evidence map›Paper›PMID 30653209›Full record

Trial reportJAMA oncology2019

Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ Treatment.

Constance D Lehman, Constantine Gatsonis, Justin Romanoff, Seema A Khan, Ruth Carlos, Lawrence J Solin, Sunil Badve, Worta McCaskill-Stevens, Ralph L Corsetti, Habib Rahbar and 11 more

Registry-linked trialOpen access · bronzeAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in JAMA oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02352883 (Prospective Study of Magnetic Resonance Imaging), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02352883 naactive not recruitingnot on this map

Prospective Study of Magnetic Resonance Imaging (MRI) and Multiparameter Gene Expression Assay in Ductal Carcinoma In Situ (DCIS)

TypeinterventionalSponsorECOG-ACRIN Cancer Research GroupRan2015 to 2027Enrolled368ConditionsDuctal Breast Carcinoma In SituArmsMagnetic Resonance Imaging, Therapeutic Conventional Surgery, Therapeutic Surgical Procedure, Radiation Therapy, Endocrine Therapy
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Review
  11. Overcoming Barriers in Ductal Carcinoma In Situ Management: From Overtreatment to Optimal Treatment.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Article
  12. Article
  13. Article
  14. Article
  15. De-Escalation of Locoregional Therapy in Low-Risk Disease for DCIS and Early-Stage Invasive Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
    Review
  16. Imaging in Locoregional Management of Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
    Review
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 16 institutions in 1 country.

Constance D LehmanDepartment of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.
Constantine GatsonisCenter for Statistical Sciences, Brown University School of Public Health, Providence, Rhode Island.
Justin RomanoffCenter for Statistical Sciences, Brown University School of Public Health, Providence, Rhode Island.
Seema A KhanDepartment of Surgery, Northwestern University, Chicago, Illinois.
Ruth CarlosDepartment of Radiology, University of Michigan, Ann Arbor.
Lawrence J SolinDepartment of Radiation Oncology, Albert Einstein Healthcare Network, Philadelphia, Pennsylvania.
Sunil BadveDepartment of Pathology, Indiana University, Indianapolis.
Worta McCaskill-StevensNational Cancer Institute, Bethesda, Maryland.
Ralph L CorsettiDepartment of Surgical Oncology, Ochsner Medical Center, New Orleans, Louisiana.
Habib RahbarDepartment of Radiology, University of Washington, Seattle.
Derrick W SpellGulf South National Cancer Institute Community Oncology Research Program, New Orleans, Louisiana.
Kenneth B BlanksteinDepartment of Medical Oncology, Hunterdon Medical Center, Flemington, New Jersey.
Linda K HanDepartment of Pathology, Indiana University, Indianapolis.
Jennifer L SabolDepartment of Surgical Oncology, Lankenau Medical Center, Wynnewood, Pennsylvania.
John R BumberryDepartment of Surgery, Mercy Hospital, Springfield, Missouri.
Ilana GareenCenter for Statistical Sciences, Brown University School of Public Health, Providence, Rhode Island.
Bradley S SnyderCenter for Statistical Sciences, Brown University School of Public Health, Providence, Rhode Island.
Lynne I WagnerDepartment of Social Science and Health Policy, Wake Forest University Health Sciences, Winston Salem, North Carolina.
Kathy D MillerDepartment of Pathology, Indiana University, Indianapolis.
Joseph A SparanoDepartment of Medical Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.
Christopher ComstockDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Brown University · USIndiana University – Purdue University Indianapolis · USEinstein Healthcare Network · USHarvard University · USHunterdon Medical Center · USLankenau Medical Center · USLouisiana Cancer Research Center · USMemorial Sloan Kettering Cancer Center · USMercy Hospital Springfield · USMontefiore Medical Center · USNational Cancer Institute · USNorthwestern University · USOchsner Medical Center · USUniversity of Michigan–Ann Arbor · USUniversity of Washington · USWake Forest University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
ECOG-ACRIN NCORP Research Base - TMISTUG1CA189828 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · 2014 to 2026
$199.7M
Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6M
ECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · 2015 to 2026
$41.1M
Montefiore Academic Community NCORP ProgramUG1CA189859 · NCI · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI Balazs Halmos, Della Makower · 2014 to 2026
$10.8M
Hutchinson Center as Lead Academic Participating Site (UG1)UG1CA233328 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Evan Yu · 2019 to 2026
$4.3M
NCI NIH HHS P30 CA008748NCI NIH HHS U10 CA180820NCI NIH HHS U24 CA196172NCI NIH HHS UG1 CA189828NCI NIH HHS UG1 CA189859NCI NIH HHS UG1 CA233328
6 · The paper itself

Abstract

importanceAdvanced diagnostics, such as magnetic resonance imaging (MRI) and gene expression profiles, are potentially useful to guide targeted treatment in patients with ductal carcinoma in situ (DCIS).

objectivesTo examine the proportion of patients who converted to mastectomy after MRI and the reasons for those conversions and to measure patient adherence to radiotherapy guided by the 12-gene DCIS score. DESIGN, SETTING, AND

participantsAnalysis of a prospective, cohort, nonrandomized clinical trial that enrolled women with DCIS on core biopsy who were candidates for wide local excision (WLE) from 75 institutions from March 25, 2015, to April 27, 2016, through the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network trial E4112.

interventionsParticipants underwent breast MRI before surgery, and subsequent management incorporated MRI findings for choice of surgery. The DCIS score was used to guide radiotherapy recommendations among women with DCIS who had WLE as the final procedure and had tumor-free excision margins of 2 mm or greater. MAIN OUTCOMES AND MEASURES: The primary end point was to estimate the conversion rate to mastectomy and the reason for conversion.

resultsOf 339 evaluable women (mean [SD] age, 59.1 [10.1] years; 262 [77.3%] of European descent) eligible for WLE before MRI, 65 (19.2%; 95% CI, 15.3%-23.7%) converted to mastectomy. Of these 65 patients, conversion was based on MRI findings in 25 (38.5%), patient preference in 25 (38.5%), positive margins after attempted WLE in 10 (15.4%), positive genetic test results in 3 (4.6%), and contraindication to radiotherapy in 2 (3.1%). Among the 285 who had WLE performed after MRI as the first surgical procedure, 274 (96.1%) achieved successful breast conservation. Of 171 women eligible for radiotherapy guided by DCIS score (clear margins, absence of invasive disease, and score obtained), the score was low (<39) in 82 (48.0%; 95% CI, 40.6%-55.4%) and intermediate-high (≥39) in 89 (52.0%; 95% CI, 44.6%-59.4%). Of these 171 patients, 159 (93.0%) were adherent with recommendations. CONCLUSIONS AND RELEVANCE: Among women with DCIS who were WLE candidates based on conventional imaging, multiple factors were associated with conversion to mastectomy. This study may provide useful preliminary information required for designing a planned randomized clinical trial to determine the effect of MRI and DCIS score on surgical management, radiotherapy, overall resource use, and clinical outcomes, with the ultimate goal of achieving greater therapeutic precision.

trial registrationClinicalTrials.gov identifier: NCT02352883.

Indexed as

Breast NeoplasmsCarcinoma, Ductal, BreastMagnetic Resonance ImagingTranscriptomeAgedCross-Over StudiesDecision MakingFemaleHumansMastectomyMiddle AgedPatient Acceptance of Health Care

Identifiers

PMID30653209
PMCPMC6583020
OpenAlexW2911206691

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.